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Non-Equivalent Ligand Selectivity of Agonist Sites in (a4b2)2a4 Nicotinic
Acetylcholine Receptors: A Key Determinant of Agonist Efficacy
Simone Mazzaferro, Federica Gasparri, karina New, Constanza Alcaino,
Isabel Bermudez.
Biological and Medical Sciences, Oxford Brookes University, Oxford,
United Kingdom.
The a4b2 nicotinic acetylcholine receptor (nAChR) is the most abundant
nAChR type in the brain, and this type plays a pivotal role in the reinforcing
and rewarding effects of nicotine. The a4b2 nAChR exists in alternate
(a4b2)2 a4 and (a4b2)2b2 forms, which are activated by agonists with strik-
ingly differing efficacies. Recent breakthroughs have identified an additional
operational agonist binding site in the (a4b2)2a4 nAChR that increases the
maximal responses to ACh.
In this study, we characterised the ligand selectivity of the individual agonist
sites of the (a4b2)2a4 nAChR to determine whether differences in agonist
selectivity influences agonist efficacy. Applying the substituted cysteine acces-
sibility method to individual agonist sites in concatenated (a4b2)2a4 receptors,
we determined the agonist selectivity of the agonist sites of the (a4b2)2a4 re-
ceptor. We show that (a) the rate of covalent modification of substituted cyste-
ines depends on the subunit interface at which the modification occurs and b)
that agonists such as sazetidine-A and TC-2559 are excluded from the site at
the a4/a4 interface. Given that additional binding to the agonist site in the
a4/a4 interface, increases ACh efficacy and that agonists excluded from the
agonist site at the a4/a4 interface behave as partial agonists, we conclude
that the ability to engage all agonist sites in (a4b2)2a4 nAChRs is a key deter-
minant of agonist efficacy. The findings add another level of complexity to the
structural mechanisms that govern agonist efficacy in heteromeric nAChRs and
related ligand gated ion channels.
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Desformylflustrabromine Potentiates High-Sensitivity a4b2 Receptors by
Increasing Channel Opening Rate
Arianna Demmerly, Brian W. Edmonds.
Chemistry & Biochemistry, University of Alaska Fairbanks, Fairbanks,
AK, USA.
Desformylflustrabromine (dFBr) is a positive allosteric modulator of a4b2
neuronal nicotinic receptors (nAChRs). Investigations of mechanisms of
nAChR modulators may facilitate the development of new therapeutic drugs
that offset or correct errors in signaling associated with Alzheimer’s disease,
nicotine addiction, and other disorders of cholinergic signaling. We made
steady-state, cell-attached patch-clamp recordings of 20 pS, high-sensitivity
(HS) human a4b2 receptors stably expressed in HEK-293 cells. We developed
6-state gating models from data acquired with 1 mM ACh with and without
1 mM dFBr. Models included two sequential ligand-binding reactions leading
to a desensitized state (C14C24C34D), and mono- and diliganded open-
ings (O1 and O2) from C2 and C3, respectively. Rate constants governing tran-
sitions between connected states were obtained by fitting single-channel data
to the model (constraints: C1/C2 ¼ 2,C2/C3 and C3/C2¼2,C2/C1)
using a maximum likelihood method implemented in QUB. dFBr increased
binding and unbinding rates for ACh (2.6- and 2-fold, respectively), the open-
ing rate (C3/O2) for diliganded receptors (4.8-fold), and the (microscopic)
desensitization rate (5.3-fold). Simulations of macroscopic responses to
concentration-jumps (range: 0.1 mM - 100 mM) revealed that the enhanced
rate into O2 yielded approximately 2 to 3-fold potentiation of peak currents
(maximal Popen in 100 mM ACh ¼ 0.29) despite the fact that potentiation
was blunted by the enhanced rate of desensitization. Moreover, at ACh concen-
trations above 10 mM, our data are consistent with the interpretation that poten-
tiation of HS receptor responses to dFBr arises not from modulation of ligand
binding rates, but from an increase in the rate of channel opening, correspond-
ing to a decrease in the latency to first opening and a reduction in the time to
peak current (ACh 23 ms; dFBr 8 ms) of simulated macroscopic responses.
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Is the AChR a Cuckoo-Clock? Local and Remote Interactions of the aM2-
3 Linker in Gating
Shaweta Gupta, Prasad Purohit, Anthony Auerbach.
Physiology and Biophysics, University at Buffalo, Buffalo, NY, USA.
The aM2-3 linker of pentameric ligand-gated ion channels (18-residues in
AChRs) is at the interface of the extracellular and transmembrane domains,
which twist relative to each other early in the channel-opening process
(phi~0.7). Phi-analyses of mouse muscle AChRs indicate that residues in this
linker and those at the transmitter binding sites share a common, even-earlierposition in the gating transition state (phi~0.9). To understand the mechanism
for the similar behavior of these two separated regions (~30 A˚), whose combined
motions appear to trigger channel-opening, we used single-channel free-energy
mutant cycle analyses (A-A pairs) to measure the extents to which a-subunit
linker residues (265-268) interactwith other amino acids. The significant interac-
tions (>0.5 kcal/mol) were as follows (n pairs tested; energies in kcal/mol): i)
aloop2 (7), aE45-aP265 ~þ3.5 (positive is unfavorable); ii) acys-loop (2),
aV132-aS268 ~þ1; iii) agonist sites (3), aS268 and aY93 or aY198 showed
no coupling but the interaction with aY190 was ~-1.2 (favorable); iv)
intra-linker (4), no significant coupling; v) εloop9 (6), εG183-aS268 and
εG183-aT267~þ1.4; vi) εpre-M1 (1), εL221-aT267, no coupling. The large, un-
favorable interaction between aP265 and its loop 2 neighbor aE45 (~5 A˚
separation in GLIC) suggests that these side chains share a common energetic
environment that is perturbed by the gating conformational change (twist). The
long-distance, favorable interaction between aS268A in the linker and
aY190A at the agonist site is more surprising. We hope to elucidate a network
of apposed residues whose shared energy changes might be associated with the
twist. More importantly, we are exploring the possibility that there is a long-
distance energy transfer between the agonist binding site and transmembrane
domain via the backbone that is not by a cuckoo-clock-like mechanical linkage.
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Molecular Simulations of Muscle AChR Agonist Binding Sites
Srirupa Chakraborty1, Tapan K. Nayak1, Iva Bruhova1, Wenjun Zheng2,
Anthony L. Auerbach1.
1Biophysics, State University of New York at Buffalo, Buffalo, NY, USA,
2Physics, State University of New York at Buffalo, Buffalo, NY, USA.
We are attempting to design and control the agonist binding properties of mus-
cle acetylcholine receptors (AChRs). These hetero-pentamers have 2 trans-
mitter binding sites in the extracellular domain, at a-d and either a-g (fetal)
or a-ε (adult) subunit interfaces. We used computational modeling and MD
simulation to investigate the structural dynamics and energetics of these 3
different binding interfaces. Starting from an Aplysia AChBP crystal structure
(PDB id 2BYQ), we used homology modeling to build all-atom dimer and pen-
tamer models of the extracellular domain, and docked acetylcholine (ACh) as
the ligand. MD simulations (Charmm27) were run to obtain binding free en-
ergies at all 3 interfaces. The a-d and a-ε sites were found to be approximately
equivalent, but a-g provided ~33% more favorable binding energy, which is in
good agreement with experimental, single-channel electrophysiology results
(Nayak and Auerbach, PNAS 2013). In the model, the packing of five aromatic
residues is tighter, the tryptophan residues 149 and 55 are more orthogonal and
loop C less is flexible at a-g compared to the others. The dimer and pentamer
models gave similar binding energies, supporting the experimental observation
that the agonist sites behave independently. We are using the model as a tool, to
identify residues in the ε and d subunits that are responsible for the lower ACh
binding energy and, hence, to guide the wet-bench experiments. We targeted
nine amino acids that are homologous in d and ε but different in g, within 20
A˚ of the quaternary ammonium of ACh. In the pentamer simulations, swapping
all of these between a-d and a-g resulted in a full switch of the structures and
energies. We are testing various subsets of these mutations in order to suggest a
minimum construct that can be verified by using electrophysiology.
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Differences in Agonist Energy at the Neurotransmitter Binding Sites in the
Neuromuscular Acetylcholine Receptors
Tapan K. Nayak, Anthony Auerbach.
Physiology and Biophysics, SUNY @ Buffalo, Buffalo, NY, USA.
Each neuromuscular AChR has 2 agonist binding sites located in the extra-
cellular domain, at ad and either aε (adult) or ag (fetal) subunit interfaces.
Though in most species g- is replaced by the ε-subunit during perinatal devel-
opment, the rationale for the subunit swap is little understood. We used single-
channel electrophysiology to measure the effects of mutations of 5 conserved
aromatic residues at each type of agonist site, with regard to their contribution
to the free energy of agonist binding to active vs. resting receptors (DGB1; in
mouse AChRs with only 1 functional binding site expressed in HEK cells).
The agonist binding sites in both adult and fetal AChRs operate independently.
For 4 different agonists (including ACh and choline) DGB1 is ~-2 kcal/mol
more favorable at ag compared to aε and ad. Of the aromatic residues, only
3 contribute to the DGB1 at the adult sites (aY190, aY198 and aW149),
whereas all 5 do so at ag (including aY93 and gW55). The non-a tryptophan
(W55) is a variable energy source that makes a huge contribution to DGB1 only
at ag, where it shapes the binding pocket by interacting with some of the a-sub-
unit aromatics. The hydroxyl and benzene groups of loop C residues aY190 and
aY198 behave similarly at all three kinds of site, but the benzene of aY93 con-
tributes to DGB1 only at ag. We are studying other residues on the non-a side of
430a Tuesday, February 10, 2015the pocket for their contribution to DGB1 to understand the interactome network
at the three binding sites. It is possible that the different sensitivities of the fetal
a-g site vs. the adult a-ε and a-d sites to ACh and choline are important for the
proper maturation and function of the neuromuscular synapse.
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Interaction of 7-Methoxytacrine-Adamantylamine Cholinesterase Inhibi-
tors with Nicotinic and Muscarinic Acetylcholine Receptors
Ze-Jun Wang1, Vendula Sepsova2, Katarina Spilovska2,
Tasnim S. Mohamed1, Ayman K. Hamouda1,3.
1Dept. of Pharmaceutical Sciences, Texas A&M Health Science Center,
Kingsville, TX, USA, 2Dept. of Toxicology, University of Defense, Hradec
Kralove, Czech Republic, 3Dept. of Neuroscience and Experimental
Therapeutics, Texas A&M Health Science Center, Bryan, TX, USA.
Acetylcholinesterase inhibitors (AChEI) and the N-methyl-D-aspartate
(NMDA) receptor antagonist memantine are among the few FDA-approved
drugs for Alzheimer’s disease. In effort to develop multi-target (AChE-
NMDA)-directed ligands for the treatment of Alzheimer’s disease, a series 7-
Methoxytacrine-Adamantylamine thiourea heterodimers have been synthesized
and evaluated for their effects as AChEI (Spilovska et. al. 2013, Molecules 18,
2397-2418). In this report, we extend their pharmacological characterization
by examining their effects on neuronal and muscle-type nicotinic acetylcholine
receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). We also
compare their pharmacology to 7-Methoxytacrine-Adamantylamine urea heter-
odimers. 7-Methoxytacrine-Adamantylamine thiourea derivatives containing
2-8 carbon linkers inhibited AChE and butyrylcholinesterase (BChE) with
high potency (IC50, 0.5-6 mM), whereas 7-Methoxytacrine-Adamantylamine
urea derivatives inhibited AChE with higher potency than BChE. None of the
tested compoundpotentiatedM1mAChRor nAChRs responses. They havemin-
imal effects on acetylcholine-induced currents in Xenopus oocytes expressing
neuronal a4b2 nAChR and inhibited M1 mAChR at higher concentrations
(IC50s>10 mM). At concentration that inhibit AChE, both thiourea and urea de-
rivatives inhibited acetylcholine-induced currents in Xenopus oocytes express-
ing muscle-type AChRs. Our preliminary results also suggest that the length
of the carbon linker affect 7-Methoxytacrine-Adamantylamine urea interactions
with AChRs, and further modifications of their structure are expected to yield
compounds with more favorable pharmacological profiles.
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Stepchild Nicotine: Effect of the Name-Giving Agonist on Muscle-Type
Nicotinic Acetylcholine Receptor
Abhilasha Ladha, Klaus Benndorf, Jana Kusch.
Institute of Physiology II, University Hospital, Jena, Germany.
Muscle-type nicotinic acetylcholine receptors (nAChRs) mediate fast synaptic
cholinergic responses at neuromuscular junctions. The adult subtype of the re-
ceptor is composed of a1, b1, d, and ε subunits in the ratio 2:1:1:1. Although
nicotine is the name-giving agonist for ionotropic acetylcholine receptors, only
a few studies investigated its effect of nicotine on this specific nAChR subtype.
A comprehensive knowledge of the mechanism underlying the nicotine-
induced gating is still missing.
For this reason, we had a closer look to macroscopic (a1)2b1dε receptor cur-
rents evoked by fast nicotine jumps and compared them with acetylcholine-
evoked responses. The receptors were heterologously expressed in HEK293
cells. After lifting and positioning the cells in front of a piezo-driven double-
barreled application pipette, whole-cell currents were monitored.
Herein, nicotine was found to be an agonist with a relative potency of about
0.60 compared to the full agonist acetylcholine. The efficiency was about
30 times lower than for acetylcholine (EC50 ¼ 97.0 mM versus EC50 ¼
3.35 mM). When activated by nicotine, (a1)2b1dε receptors desensitize slower
than receptors activated by acetylcholine. As expected from single-channel
analysis (Akk and Auerbach, Br J Pharmacol. 128:1467-76, 1999; Jadey
et al., J Gen Physiol. 141:95-104, 2013), off-currents, occurring after removal
of high nicotine concentrations, confirmed the idea of nicotine acting as a chan-
nel blocker at concentrations higher than 1 mM.
In summary, the data provide new insight into the nicotine-induced gating of
adult muscle-type receptors. The differences in comparison to the physiological
ligand acetylcholine and the action of nicotine as a partial agonist are discussed.
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The Role of the M3 Helix in AChR Gating and PAM Action
Aashutosh Vihani, Prasad Purohit, Anthony Auerbach.
University at Buffalo, Buffalo, NY, USA.
We are examining the M3 transmembrane helix of mouse muscle AChRs with
regard to C4O gating and the effects of positive allosteric modulators
(PAMs). The relative ground and transition state gating energies were estimatedfrom single-channel currents of AChRs havingM3mutations.Diliganded gating
rate and equilibrium constants were measured for ~100 mutations in 5 subunits
(a, b, d, ε and g; 20 mM choline or 500 mMACh,100mV, HEK cells). In gen-
eral: i) the effects of themutationswere small (%1 kcal/mol), ii) the effects were
similar among subunits, iii) the mutations in different subunits were indepen-
dent, iv) the mutations have no effect on the energy from the agonist affinity
change (%~0.3 kcal/mol) and v) most phi values were low (~0.3). Crystal struc-
tures ofAChRhomologues in detergents suggest that the low phi positions inM3
are interaction sites for PAMs. We investigated the actions of PNU-120596 and
IVM(1-1000nM). InWTAChRs (adult and fetal) these ligands increase substan-
tially the frequency and lifetime of constitutive openings in a manner consistent
with action at a low-phi position such as in M3. Such potentiation was also
apparent at low [agonist] (<1mMACh or choline), but at higher [agonist] gating
kinetics became complex and the potentiation was less clear. The PAMs also
increased substantially the frequency and lifetime of constitutive openings in
some of the M3 mutants (to W).
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Modal Gating of Muscle AChRs having Loop C Mutations
Ridhima Vij.
SUNY Buffalo, Buffalo, NY, USA.
Many ion channels exhibit multiple patterns of kinetic activity (‘modes’) in
single-channel currents. This behavior is rare in WT mouse muscle acetylcho-
line receptors (AChRs), where A2C4A2O gating events are well-described by
single exponentials. We have found that mutations of all loop C residues at the
transmitter binding site (except aY190 and aY198) increase the probability of
modes. The free energy of diliganded gating is the sum of that for unliganded
gating and from agonist affinity-changes at 2 binding sites: DG2¼DG0þ2DGB.
For WT adult AChRs these values are (100 mV; kcal/mol): 1.9, þ8.3 and
5.1 (ACh). All mutations of aP197 (ACDEGIKSVY) had at least 2 gating
modes with all agonists (ACh, Cho, CCh and TMA). We focused on
aP197A and ACh and Cho. There were 3 distinct modes at saturating [agonist]
but only 1 mode without agonist. Hence, the kinetic heterogeneity for this
construct is generated by fluctuations in DGB. DDGB was estimated for each
mode (kcal/mol) for ACh (1.7, WT and þ1.6) and Cho (2.2, WT and
þ0.9). That is, the gating equilibrium constant for one mode was ~30-times
larger than the WT (for both agonists), for another was about the same as the
WT and for the third was ~8-times smaller. An added F mutation at aY190
or aW149 reduced modal gating whereas one at aY198 or aY93 did not. An
F substitution at εW55 had no effect, but one at dW57 reduced the modes.
We also examined AChRs having only 1 active binding site and observed
less heterogeneity from aP197A at the fetal a-g site vs. the adult a-ε or a-d
sites. Our working hypothesis is that mutations in loop C allow the agonist
to sample multiple, meta-stable positions within the binding pocket, to produce
distinct DGB values.
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Dissecting the Inhibitory and Potentiation Effects of Desformylflustrabro-
mine on a Muscle-Type Nicotinic Acetylcholine Receptor (NACHR)
Tasnim S. Mohamed1, Ze-Jun Wang1, Tiffany R. Trevino1,
Ayman K. Hamouda1,2.
1Pharmaceutical Sciences, Texas A&M Health Science Center, Kingsville,
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Desformylflustrabromine (dFBr) potentiates 4b2 nAChR in vitro (Kim
et al. 2007, Biorg. Med. Chem. Lett. 17: 4855) and reduces nicotine self-
administration in vivo (Liu 2013; Psychopharmacology 230: 203). We have
reported that dFBr is a potent inhibitor (IC50, ~1 M) of human (Ha12b1εd) and
Torpedo (Ta12b1gd) muscle-type nAChRs. We also found, using [
3H]dFBr
reversible binding and dFBr displacement of [3H]PCP binding, that dFBr binds
with high affinity to the muscle-type nAChRs ion channel in the desensitized
state. But, when we photolabeled nAChR-rich Torpedo membranes with [3H]
dFBr in the presence of agonist, four dFBr binding sites were evident. [3H]
dFBr photolabeled amino acids in the ion channel and in three binding siteswithin
the extracellular domain previously identified for nAChRs PAMs galanthamine
andphysostigmine.The high affinity binding of dFBr in the ion channel precludes
the ability to study the functional contribution of dFBr binding within the extra-
cellular domain and to determine whether dFBr acts as inhibitor or potentiator at
these sites. Therefore, we are introducing mutations in the muscle-type nAChR
ion channel M2 helices to eliminate the channel blocking effect of dFBr. The ef-
fect of M2 mutations on the EC50 of ACh and on dFBr inhibition of muscle-type
nAChRwere examined using two-electrode voltage clamp recording. Serine sub-
stitutions of the leucine at M2-9 of each nAChR subunit decreased dFBr IC50
compared with wild-type, consistent with an open channel blocking mechanism.
This results confirm our [3H]dFBr the photolabeling results demonstrating that
